Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-FR Version v3-EN
Language French English
Date Updated 2018-01-19 2017-11-16
Drug Identification Number 02347393 02347393
Brand name MENVEO MENVEO
Common or Proper name Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine
Company Name GLAXOSMITHKLINE INC GLAXOSMITHKLINE INC
Ingredients MENINGOCOCCAL GROUP C OLIGOSACCHARIDE CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN MENINGOCOCCAL GROUP A OLIGOSACCHARIDE MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE MENINGOCOCCAL GROUP C OLIGOSACCHARIDE CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN MENINGOCOCCAL GROUP A OLIGOSACCHARIDE MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE
Strength(s) 5MCG 47MCG 10MCG 5MCG 5MCG 5MCG 47MCG 10MCG 5MCG 5MCG
Dosage form(s) SOLUTION POWDER FOR SOLUTION SOLUTION POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1 dose 1 dose
ATC code J07AH J07AH
ATC description BACTERIAL VACCINES BACTERIAL VACCINES
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2017-11-29
Actual start date 2017-12-06
Estimated end date 2018-01-18 2017-12-21
Actual end date 2018-01-17
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Menveo 5 dose format still available. Supply disruptions may be seen in the private market. Menveo 5 dose format still available. Supply disruptions may be seen in the private market.
Health Canada comments